Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ImClone Narrows Focus To VEGFR2 In Breast Cancer Phase III Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

Pivotal study is expected this year with the compound in gastric tumors as well.

You may also be interested in...



ImClone’s Late-stage Pipeline Includes A Potential Erbitux Competitor

Five new antibodies in cancer clinical trials sweeten takeover pot for BMS.

FLEX Shows Erbitux’s Strength With Survival Benefit In NSCLC

Bristol-Myers Squibb/ImClone/MerckKGaA’s cetuximab significantly prolongs survival in the first-line treatment of NCSLC.

Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone

In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068220

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel